

Keynote Speaker

Cheng-I Wang, Ph.D.

Head of the Human Monoclonal Antibody Technology Platform,
Singapore Immunology Network (SIgN),
Agency for Science, Technology and Research (A*STAR)



Engineering Cancer Immunotherapy

Dr. Cheng-I Wang joined Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR) in 2009 as the head of the Therapeutic Antibody Technology Laboratory. His research focuses on the discovery, engineering and development of fully human antibodies against infection, immune disorders, and cancers using a combination of structure-based rational design and combinatorial approaches. In the last few years, his research has extended into the cancer cell therapy field, utilizing protein and antibody engineering techniques to design novel functions in chimeric antigen receptor (CAR) T cells to address obstacles faced by current technologies. Dr. Wang is a co-founder of the A*STAR spinoff biotech company, Euchloe Bio, founded in 2016 and now part of the T cell therapy company Tessa Therapeutics. Dr. Wang received his Ph.D. in Chemistry from Washington University and postdoctoral training in the Department of Pharmaceutical Chemistry at the University of California, San Francisco.